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ARTICLE

OPEN

Mutant LRRK2 in lymphocytes regulates neurodegeneration
via IL-6 in an inﬂammatory model of Parkinson’s disease
Elena Kozina1, Matthew Byrne

1

and Richard Jay Smeyne

1✉

Mutations in a number of genes contribute to development of Parkinson’s disease (PD), including several within the LRRK2 gene.
However, little is known about the signals that underlie LRRK2-mediated neuronal loss. One clue resides in the ﬁnding that the
neurodegenerative cascades emanate from signals arising from the peripheral immune system. Here, using two chimeric mouse
models, we demonstrate that: 1) the replacement of mutant LRRK2 with wt form of the protein in T- and B-lymphocytes diminishes
LPS-mediated inﬂammation and rescues the SNpc DA neuron loss in the mutant LRRK2 brain; 2) the presence of G2019S or R1441G
LRRK2 mutation in lymphocytes alone is sufﬁcient for LPS-induced DA neuron loss in the genotypically wt brain; and 3)
neutralization of peripheral IL-6 overproduction prevents the SNpc DA neuron loss in LPS-treated mutant LRRK2 mice. These results
represent a major paradigm shift in our understanding of PD pathogenesis and suggest that immune dysfunction in some forms of
familial PD may have primacy over the CNS as the initiating site of the disorder.
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INTRODUCTION
Parkinson’s disease (PD), the second most common neurodegenerative disorder, is a major public health predicament affecting
over 6 million people1 with estimates that this number will rise to
12 million by 20402. Pathologically within the CNS, PD is
characterized by the progressive loss of dopamine (DA) neurons
in the substantia nigra pars compacta (SNpc), the presence of
intracellular α-synuclein-positive inclusions (Lewy bodies), and
decreased DA in the striatum3. PD also manifests with other nonmotor symptoms including olfactory impairment, depression,
autonomic dysfunction, sleep disturbances, and gut dysbiosis4.
Symptomatic treatment for the motor symptoms of PD primarily
involves DA-replacement therapy, but no currently available
treatment has been demonstrated to stop or slow down the
progression of this disease. Although PD has been historically
viewed as a brain-speciﬁc disease, it is clear that it also affects
other systems and organs. Recent evidence from clinical and
experimental studies suggests an inﬂuential, yet largely underappreciated, force in PD pathogenesis, that of immune signals
originating outside the brain. Indeed, one of the most common
features of both familial and sporadic PD is dysregulated
peripheral immunity5–10. Numerous human studies over the past
years have reported alterations in cytokines in PD patients
bioﬂuids (both, serum and CSF)11, impaired monocytes phagocytic
activity12, a distinct transcriptomic proﬁle of peripheral monocytes13, an unbalance in Th cells toward the pro-inﬂammatory
phenotypes14, decrease in Treg ability to suppress the activity of
Teff cells15–17 and the presence of α-synuclein reactive T-cells in
the blood of newly diagnosed PD patients18. In addition, GWAS
have recently implicated several SNPs in HLA-DR regions which
are associated with late-onset idiopathic PD further indicating a
role for the immune system in PD susceptibility19. There is also
growing awareness within the scientiﬁc community of the strong
connection between intestinal inﬂammation and the changes in
the composition of intestinal bacterial populations related to PD
pathogenesis20–22. Recent studies also demonstrated increased

levels of endotoxin in PD patients’ blood, especially those with a
higher risk for dementia, as well as greater gastrointestinal
permeability with lower levels of LPS-binding protein and
increased gut staining for E. coli suggesting an active role for
bacterial infection in the outcome of the disease23,24. Thus, it is
now proposed that the immune component in PD occurs early
and changes dynamically with the disease progression, contributing to the neuronal loss observed in patients.
While the vast majority of PD cases arise from unknown causes,
about 10–15% have a clear genetic etiology25. At this time, over 90
loci have been associated with PD26, although only a small
number of them, including the gene encoding Leucine Rich
Repeat Kinase 2 (LRRK2), account for the majority of familial
cases27. LRRK2 is known to express in both innate and adaptive
immune cells and its expression is tightly regulated by immune
stimulation28–34. It has also been shown that LRRK2 expression is
signiﬁcantly increased in inﬂamed intestinal tissue biopsied from
patients with Crohn’s disease, indicating that LRRK2 might play a
more generalized role in the inﬂammatory process than previously
recognized28. A number of studies have shown that peripheral
pro-inﬂammatory cytokine responses to challenge were altered in
mice carrying the LRRK2 mutation35–37 as well as in asymptomatic
PD patients carrying a G2019S LRRK2 mutation38; suggesting a
role for LRRK2 in peripheral inﬂammation. Our group has recently
shown that mice carrying two most common pathogenic LRRK2
mutations, G2019S or R1441G, develop a signiﬁcantly higher LPSinduced SNpc DA cell loss. We also found that the exacerbated
neuroinﬂammation and SNpc DA cell loss do not depend on the
active participation of the brain resident microglia or inﬁltrating
T-cells and/or monocytes, but are likely mediated by circulating
inﬂammatory molecules that are dysregulated by mutant LRRK237.
Based on these studies, we now propose that the neurodegenerative cascades in PD emanate from signals arising from the
peripheral immune system and that LRRK2-PD is primarily an
immune disorder, with secondary effects manifested in the CNS.
Since the majority of PD studies focus on the events within the
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CNS and the contribution of peripheral immune compartments is
largely ignored, in this study we have asked a fundamental
question: is altered peripheral immune response alone sufﬁcient
to initiate neuronal loss in LRRK2-PD?
To test this hypothesis, we generated chimeric mice with a wt
adaptive immune system and a LRRK2 mutant brain (and vice
versa) and then examined whether this in vivo “switching” impacts
both peripheral and CNS inﬂammatory response and SNpc DA cell
loss following exposure to LPS. Herein, we report that the
replacement of mutant LRRK2 with wt LRRK2 in peripheral Tand B-cells diminishes the peripheral inﬂammatory response to
LPS and rescues SNpc DA neuron loss that is observed in fully
mutant LRRK2 mice. Additionally, “reversed” chimera mice
carrying normal wt LRRK2 in the brain but mutant LRRK2
(R1441G or G2019S) in the adaptive immune cells do manifest
the LPS-induced SNpc DA neuron loss identical to LPS-treated fully
mutant LRRK2 mice. Furthermore, we identiﬁed peripheral IL-6 as
a key component of inﬂammation-mediated neuronal loss since
neutralization of LPS-induced IL-6 overproduction in R1441G
LRRK2 mutants completely abolishes the SNpc DA cell loss. Based
on these data we suggest that LRRK2-induced immune dysfunction in PD is not simply a manifestation of the pathology, but
primarily drives the development of the disorder, and propose the
provocative hypothesis that LRRK2-PD has its etiologies in a
malfunction of the adaptive immune response.
RESULTS
Generation of BM chimeras and characterization of immune
phenotype
Given that irradiation severely damages both innate and adaptive
immune systems as well as the CNS39–43, we ﬁrst decided to verify
whether efﬁcient donor cells engraftment can be achieved in
homozygous immunodeﬁcient Rag1−/− recipients without a preconditioning regimen (Supplementary Fig. 1a). Rag1−/− mice lack
mature T- and B-lymphocytes as a result of the deﬁcit in V(D)J
recombination44. In contrast to SCID mice, which develop some
functional lymphocytes with age, the phenotype of Rag1−/− mice
is described as a “non-leaky” immunodeﬁciency which makes this
strain an ideal candidate for immune repopulation via bone
marrow transplantation (BMT). Furthermore, Rag1−/− mice have
previously been examined for evidence of any inherent neuropathology, and no histopathological (including the loss of nigral
DA neurons or microglia activation) or behavioral abnormalities
related to a PD phenotype were observed45,46.
Flow cytometry analysis of peripheral mononuclear cells and
splenocytes isolated from Rag1 chimeras 8 weeks posttransplantation with GFP BM cells revealed that reconstitution
efﬁcacy (% of GFP-positive cells/total live cells) was about 80% in
both PBMCs (Supplementary Fig. 1b, c) and spleen (data not
shown). Importantly, only CD19+, CD4+, and CD8 + cells were
GFP-positive, while CD11b + cells (monocytes) were GFP-negative
suggesting that the host innate immune system remained intact
after BMT (Supplementary Fig. 1d). Since Rag1−/− mice fail to
generate antibodies due to impaired B-cell development44, we
next assessed whether antibody production was restored in BMtransplanted mice. We found that 8 weeks post-BMT, antibody
production in chimeras completely returned to the WT level
(Supplementary Fig. 2a). To ensure that cytokines, which are overproduced in Rag1−/− due to the lack of T-cell mediated inhibition
of innate immunity47, also returned to the normal level in BMtransplanted chimeras, we next measured serum cytokines and
chemokines in naïve and LPS-treated Rag1 chimeric mice. We
showed that BMT normalized both baseline and stimuli-induced
cytokine response in Rag1 chimeras to the WT level (Supplementary Fig. 2b, c).
npj Parkinson’s Disease (2022) 24

Generation of double mutant chimeras carrying wt adaptive
immune system
Having shown that chimerism and functional adaptive immune
response can be achieved in transplanted Rag1−/− mice, we next
crossed Rag1−/− mice to transgenic LRRK2 mice overexpressing
the human pathogenic R1441G mutation, and then intercrossed
these heterozygous mice to generate double mutant mice (Fig.
1a). Genotypes of double-mutant mice were conﬁrmed in each
experiment and only homozygous Rag1−/−/R1441Gtg/tg were used
in the study. To conﬁrm that the resulting double mutants lacked
T- and B-cells similar to the parental Rag1−/− strain, ﬂow
cytometry was performed on peripheral mononuclear cells
extracted from 3-month old mice. Analysis conﬁrmed that double
mutant animals, regardless of LRRK2 transgene expression, lacked
CD4+, CD8 + T-cells as well as CD19 + B lymphocytes (Fig. 1b). It
is also important to note that the number of these cells was
unchanged in immune-competent non-treated R1441G mice
compared to WT mice suggesting that mutant LRRK2 does not
alter the proportion of peripheral immune cell subsets.
We next transplanted Rag1/R1441G double mutant mice with
BM-derived from sex- and MHC-matched WT(GFP) donors. As a
result of BMT, the immune system of these chimeric mice (WT
(GFP) -> Rag1/R1441G) expressed wtLRRK2 in T- and B-cells (Fig.
1c), but their innate immune cells, as well as the CNS (and all other
cells/organs that normally express LRRK2), expressed R1441G
LRRK2. All BM-transplanted double mutant chimeras developed
normally without any signs of Graft vs Host Disease (GvHD) and
had a 0% post-BMT mortality rate. To further validate that T- and
B-cells from BM transplanted double mutant mice lack human
mutant LRRK2, we sorted double-positive GFP+/CD4+, GFP+
/CD8+, and GFP+/CD19+ cells and analyzed human and mouse
lrrk2 mRNA expression. As expected, peripheral lymphocytes from
double mutant chimeras highly express wt mouse lrrk2 (Fig. 1d)
demonstrating that T- and B-cells are WT donor-derived. Similar to
Rag1 chimeras, the baseline antibody and cytokine proﬁles in the
double mutant chimeras carrying a wt adaptive immune system
were fully restored to the control WT level (Fig. 1e, f).
Since it has been demonstrated in several disease models
including bacterial meningitis, autoimmune encephalomyelitis,
PD, and Alzheimer’s disease, as well as in certain experimental
conditions (for example, in PU.1 mice lacking all cells of myeloid
and lymphoid lineages) that BM stem cells can migrate across the
BBB and transdifferentiate into functional microglia39–41,48 or even
neurons49–51, we next assessed whether GFP + donor cells can
colonize the brain of BM-transplanted double mutant chimeras
before and/or after LPS injection. Histological analysis of GFP colocalization with Iba-1 and GFAP revealed no contribution of BMderived cells to the brain glial pool of chimeras (Supplementary
Fig. 3a), further conﬁrming that the CNS of double mutant
chimeras remained “donor cell-free”, and therefore all cells in the
brain contained a mutant LRRK2 genotype. In addition, double
mutant chimeras were examined for histopathological changes
including the loss of SNpc DA neurons (Supplementary Fig. 3b)
and microglia activation where no abnormalities were observed.
Replacement of mutant LRRK2 with wt form in peripheral Tand B-cells rescues LPS-induced SNpc DA neuron loss
To address the question of whether mutant LRRK2 mediates its
genotoxic effect through peripheral immune function, we next
treated BM-transplanted double mutant chimeras carrying only
wtLRRK2 in the adaptive immune cells with the dose of LPS
previously shown to induce SNpc DA neuron loss in fully mutant
R1441G mice52. TH-immunostaining analysis and subsequent
quantiﬁcation of midbrain sections revealed that SNpc DA neuron
loss following LPS treatment was completely abolished in double
mutant chimeras (Fig. 2a). Notably, in this experiment, LPSinduced neuronal loss in non-transplanted (e.g., immunodeﬁcient)
Published in partnership with the Parkinson’s Foundation
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Fig. 1 Breeding paradigm and immune phenotype characterization of double mutant chimeras. a Breeding diagram and BMT strategy
used to generate double mutant chimeras, (WT)GFP ->Rag1/R1441G. b Flow cytometry conﬁrmed that similar to Rag1−/− mice, nontransplanted double mutant mice lack both B- and T-lymphocytes regardless of R1441G transgene expression. Note that immune-competent
R1441G mice used as a control exhibit normal proportions of adaptive immune cells compared to WT. Data are mean ± SEM, n = 20 for WT and
R1441G groups; n = 3–4 for Rag1−/− and double mutant groups. c Representative ﬂow cytometry plot from blood of double mutant chimera
8 weeks after BMT demonstrating signiﬁcant repopulation with GFP + BM cells. d qPCR analysis showed the lack of human lrrk2 mRNA
expression in T- and B-cells sorted from BM-transplanted double mutant chimera’s (WT(GFP) -> Rag1/R1441G). Cells were sorted based on
GFP+/CD4 + (CD4-PerCP-CY5.5), GFP+/CD8 + (CD8-PE-CY7) and GFP+/CD19 + (CD19-APC-CY7) ﬂuorescent intensity. Sorted GFP- cells from
double mutant chimeras (innate immune cells) were used as a positive control for human lrrk2 mRNA expression. mRNA expression was
normalized to mouse β-actin. Data are mean ± SEM, n = 4. e, f Similar to Rag1 chimeras, serum cytokines, and antibodies are back to control
R1441G level in BM-transplanted double mutant chimeras. Data are mean ± SEM, n = 5–10 for each group. ND not detectable.

double mutant mice (Rag1/R1441G) could not be estimated since
all mice died within 1–2 h post-LPS. This rapid death was likely
attributable to a cytokine storm, as it has been shown that large
numbers of naive T-cells are needed to efﬁciently temper the
deadly TLR innate immune response at the initial phase of the
infection47. Remarkably, we found that similar to PD patients53,54,
inﬂammatory stimuli-induced SNpc DA neuron loss in R1441G
mice varies signiﬁcantly along the rostro-caudal axis of the SNpc;
being higher in the caudal section than in the rostral one, and that
this uneven pattern of DA cell loss was completely restored to the
normal level in R1441G chimeras carrying wt immune cells (Fig.
2b, d). This further conﬁrms the selective vulnerability of SNpc DA
neurons to inﬂammatory conditions. Thus, our data indicate that
normalization of mutant LRRK2 expression speciﬁcally in the
adaptive immune cells impacts the survival of SNpc DA neurons
following an exogenous inﬂammatory insult.
Reversed chimeras carrying R1441G or G2019S LRRK2 in the
adaptive immune system alone exhibit LPS-induced
neurodegeneration
To further test our hypothesis that the peripheral adaptive
immune system has primacy over the CNS innate immune system
in LPS-induced neurodegeneration, we “switched” chimerism and
generated mice that harbored mutations at the R1441G position
of LRRK2 within the cells of the adaptive immune system, while
the cells in the brain (and other cells in the body) were
genotypically wt (Fig. 2c). We then treated these animals
(R1441G ->Rag1) with the dose of LPS previously shown to induce
SNpc DA neuron loss in fully mutant R1441G mice. Stereological
analysis revealed that the reversed chimeras developed a
Published in partnership with the Parkinson’s Foundation

signiﬁcant SNpc DA neuron loss 7 days post-LPS treatment; with
the same selective vulnerability of caudal SNpc DA neurons as the
parental R1441G mice (Fig. 2b, c, d). Importantly, no SNpc DA
neuron loss was seen in LPS-treated control Rag1−/− mice
transplanted with WT(GFP) BM; suggesting that the BMT
procedure itself does not affect neuronal survival. To examine if
this peripheral effect was speciﬁc to the R1441G mutation in
LRRK2 or was common to other mutations in the LRRK2 loci, we
used BMT methods to generate mice that had mutant G2019S
LRRK2 in the cells of the peripheral immune system while
maintaining wt LRRK2 in all other cells, including neurons. The
G2019S mutation is situated in the LRRK2 MAPK domain that is
strongly associated with a constitutive kinase activation55. The
R1441G is located in the ROC domain of the LRRK2 gene56–58 but
shares common pathogenic mechanisms that lead to PD59. Similar
to fully mutant R1441G and G2019S strains, reversed G2019S
->Rag1 chimeras also develop LPS-induced neurodegeneration
(Supplementary Fig. 4). These data strongly suggest that the
genotype of the peripheral immune system, whether wt or
mutant, has primacy over the brain, although it remains to be
determined if the mechanisms for peripheral immune signaling
are the same in both mutations.
Inhibition of peripheral IL-6 rescues LPS-induced SNpc cell
loss in R1441G LRRK2 mice
To examine whether switching from mutant LRRK2 to wt in T- and
B-cells resulted in a distinct inﬂammatory response, we next
screened LPS-induced changes of predominantly proinﬂammatory cytokines in the periphery and in the brain (SN) of
WT, fully mutant R1441G and rescued double mutant chimeras
npj Parkinson’s Disease (2022) 24
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Fig. 2 Genotype of the adaptive immune system has primacy over the genotype of the brain in regard to induction of LPS-induced
neuronal loss. a Double mutant chimeras (WT(GFP)->Rag1/ R1441G) expressing wt LRRK2 in T- and B-cells show completely rescued TH cell
loss compared to LPS-treated R1441G mice. Data are mean ± SEM, n ≥ 4. *p < 0.05 vs WT or vs group indicated on the graph. b Rostro-caudal
gradient of DA cell loss seen in R1441G mice was restored in double mutant chimeras carrying wt immune cells and mimicked in reversed
chimeras carrying mutant T- and B-cells. c Reversed chimeras expressing mutant LRRK2 only in adaptive immune cells develop SNpc TH cell
loss 7 days after LPS treatment similar to LPS-treated R1441G mice. Note that LPS-treated control Rag1−/− mice transplanted with GFP+/+ BM
did not develop LPS-induced DA cell loss. Data are mean ± SEM, n ≥ 4. *p < 0.05 vs WT or vs group indicated on the graph. d Representative
images of TH-positive DA neurons in the SNpc of WT, R1441G mice, and chimeras 7 days post-LPS injection. Sections are matched at the same
level of the SN (Bregma −3.08–3.16 mm)112. Scale bar = 100 μm.

Fig. 3 LPS-induced activation of systemic IL-6 in double mutant
chimeras is back to the WT level. Cytokines proﬁle in the serum (a)
and SN (b) of WT, R1441G, and double mutant chimeras at 4–24 h
after LPS injection. Data are mean ± SEM, n = 5–11. *p < 0.05 vs NaCl
or vs group indicated on the graph.
npj Parkinson’s Disease (2022) 24

24 h post-LPS. The proinﬂammatory cytokines examined were
shown to be upregulated in LPS-treated mutant R1441G mice
compared to WT, with IL-6 expression showing the greatest
increase in the serum of R1441G mice 4–9 h post-LPS compared to
control animals (Fig. 3a). Notably, we observed that peripheral IL-6
expression in double mutant chimeras returned to the WT level
while expression of TNF-α and IFN-γ remained unchanged (Fig.
3a). Furthermore, IL-6 level in the SN of double mutant chimeras
also normalized to WT level 24 h post-LPS (Fig. 3b).
Given that IL-6 was the only one of these cytokines consistently
observed to be changed in rescued chimeras with wt adaptive
immune cells, we reasoned that modulation of peripheral IL-6
signaling in fully mutant LRRK2 mice might alter the program of
CNS neurodegeneration. In order to experimentally validate this
hypothesis, we treated R1441G LRRK2 mice with monoclonal antiIL-6 antibody (2.5 mg/kg b/w; i.v. injection) or mouse IgG (control)
2 h after LPS injection. This time point (2 h post-LPS) was chosen
empirically based on our ﬁnding that showed serum IL-6 levels
rapidly increased (within 1–1.5 h) after the administration of LPS
(Fig. 4a). R1441G mice treated with anti-IL-6 antibody had a
signiﬁcant reduction of serum IL-6 compared to IgG-treated
control mice, while no change was seen in its levels within the SN
(Fig. 4b), suggesting the modulation of IL-6 was entirely
peripheral. Subsequent immunohistochemical analysis revealed
that neutralization of peripheral IL-6 overproduction completely
rescued the LPS-induced SNpc DA neuron loss seen in R1441G
mice 7 days after treatment. No change in LPS-induced neuron
Published in partnership with the Parkinson’s Foundation
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Fig. 4 Inhibition of peripheral IL-6 rescues LPS-induced SNpc cell loss in R1441G mice. a Time-course of serum IL-6 secretion in R1441G
mice at different time points post-LPS. Data are mean ± SEM, n = 5–8. *p < 0.05. b Anti-IL-6 antibody signiﬁcantly inhibits LPS-induced IL-6 upregulation in serum, with no change was seen in the SN. Data are mean ± SEM, n = 3–5. *p < 0.05. For each group, data in LPS-treated groups
are expressed as the percentage of NaCl control. c Neutralization of peripheral IL-6 completely rescues LPS-induced SNpc DA neuron in
R1441G mice. Data are mean ± SEM, n ≥ 4. *p < 0.05 vs WT or vs group indicated on the graph. d Representative images of TH-positive DA
neurons in the SNpc of LPS-treated WT, R1441G, and R1441G that received either anti-IL-6 mAb or IgG. Sections are matched at the same level
of the SN (Bregma −3.08–3.16 mm) (Paxinos and Franklin, 2001). Scale bar = 100 μm.

loss was seen in a control cohort of LRRK2 mice treated with IgG
(Fig. 4c, d). These data, thus, indicate that peripheral IL-6 signaling
plays a crucial role in peripheral immune response-mediated
neuronal loss in LRRK2-PD.
DISCUSSION
In this study, using a chimeric mouse model, we provide the
evidence demonstrating that alterations in the adaptive immune
system of animals carrying LRRK2 mutations can dramatically alter
the development of the neuropathological phenotype. Speciﬁcally, we found that LPS-induced loss of DA neurons in the SNpc of
mice overexpressing pathogenic LRRK2 mutations can be
abolished by the replacement of mutant LRRK2 in T- and
B-lymphocytes with the wt form of the protein. Importantly, we
also found that harboring a genotypically wt CNS but possessing
the R1441G or G2019S LRRK2 mutation in lymphocytes alone is
sufﬁcient to sensitize nigral DA neurons to the effects of an
exogenous agent, in this case, LPS. Mechanistically, we have
identiﬁed peripheral IL-6 as a key effector of the cascade of events
that lead to LRRK2-mediated neurotoxicity. These results represent
a major paradigm shift in our understanding of PD pathogenesis
and suggest that immune dysfunction in some forms of familial
PD may have primacy over the CNS as the initiating site of the
disorder.
It is now apparent that the CNS, like other organs, is under
regular immune surveillance, and that the prevailing neuroimmune connection is not limited to localized microglia-driven
neuroinﬂammation inside the brain. In fact, growing evidence
suggests that perturbations in both peripheral innate and
adaptive immune systems have a major impact on the brain
Published in partnership with the Parkinson’s Foundation

function, behavior, and the development of neurological disorders60–63. A number of animal studies have demonstrated that
changes in the peripheral immune repertoire can signiﬁcantly
inﬂuence cognition and neuronal loss in both injury and
neurodegenerative disease models. Immunodeﬁcient SCID mice
have been shown to have impaired cognitive and emotional
behaviors were attributed speciﬁcally to CD4 + T cells60,64–66.
Other studies have shown that peripheral immune activation by
the TLR3 agonist Poly(I:C) causes synapse loss which is mediated
by CX3CR1high monocytes via TNF-α-dependent mechanisms67.
Moreover, IL-4 producing Th2 cells exert beneﬁcial effects on
neurons upon traumatic CNS injury61. Multiple reports have also
implicated a role for peripherally derived neutrophils and T-cells in
Alzheimer disease pathogenesis46,68,69. The recent discovery of a
rich diversity of peripherally originated immune cells in both
mouse and human meninges70–72, a location where these immune
cells form a direct interface with the brain parenchyma, suggests
that any alterations in the peripheral or meningeal immunity can
profoundly inﬂuence CNS homeostasis and give rise to neurological disorders. Our group has previously demonstrated that
neuroinﬂammation and neuronal loss in LRRK2-PD were not
directly associated with the recruitment of peripheral T-cells or
monocytes into the brain parenchyma, nor was it mediated
through microglial LRRK252. Similar results have been observed
ex vivo where neither LPS nor priming with α-synuclein PFFs
increased LRRK2 protein expression in murine microglia73, further
conﬁrming that LRRK2 levels in the brain resident immune cells
may not have a direct effect on inﬂammation-mediated
neuronal loss.
In contrast to brain microglia, systemically circulating
monocytes, neutrophils, T- and B- cells display a high level of
npj Parkinson’s Disease (2022) 24
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LRRK2 and its expression is induced upon immune activation28,29,74–76. An increased induction of LRRK2 protein was
observed in neutrophils and CD8+ T cells from PD patients
following stimulation with IFN-γ 32,77, while LRRK2 mRNA was
upregulated in B-cells from patients with systemic lupus
erythematosus78. Elevated LRRK2 levels were also found in
CD14+ and CD16+ monocyte subsets of PD patients79. In
regard to adaptive immunity, it has been shown that wt LRRK2
inhibits the nuclear translocation of NFAT1 (NFATc2), a master
regulator of transcriptional activation in T-cells80,81, and
negatively regulates antigen processing during phagosome
maturation82. This suggests that LRRK2 is involved in regulating
the activation status and effector functions in multiple kinds of
immune cells. These ﬁndings led us to postulate that
pathogenic PD mutations in the LRRK2 gene might contribute
to dysregulated molecular pathways in peripheral immune cells,
which in turn act as a driving force to inﬂuence the neuronal
loss. Although studies examining the microglia-mediated
neuroinﬂammation and neuronal injury in animal models of
PD are well documented (for review, see83,84), there was
currently a lack of direct evidence that peripheral immunity is
critical in the selective death of SNpc DA neurons in PD. We,
therefore, in the current study prove that under certain
inﬂammatory conditions, DA neuron loss in the SNpc completely depends on the genotype of the adaptive immune cells. We
conclude this based on our results showing that T- and B-cells
carrying a R1441G or G2019S mutation induce neurodegeneration in the normal wt brain, while lymphocytes expressing wt
LRRK2 protect the SNpc against LPS-induced neuron loss in
animals expressing mutant LRRK2 in their brain. Given that we
observed no invading lymphocytes or monocytes in the brain
parenchyma of LRRK2 mice- even after LPS treatment- we
suggest that altered peripheral immune cells might mediate
their effect either directly via systemic cytokine signals capable
of crossing the BBB (through an active transport system) or
from the meningeal space where they can release soluble
mediators that, through paracrine signaling, affect neurons and
other CNS cells. When examining cytokine expression in double
mutant chimeras expressing wt LRRK2 in T- and B-cells, we
found a signiﬁcant downregulation of LPS-induced IL-6 secretion compared to that of fully mutant R1441G LRRK2 mice; and
that attenuation of peripheral IL-6 signaling had a beneﬁcial
effect on the survival of SNpc DA neurons in LRRK2 mutants.
However, the lack of central IL-6 down-regulation upon
peripheral neutralization with antibody along with the studies
showing that systemically circulating IL-6 has only limited
ability to enter the brain’s parenchyma (0.2% of peripheral
dose)85, suggests that peripherally derived IL-6 is unlikely to
directly act on its CNS targets. This observation raises two
important questions: (i) what is the cellular source of
dysregulated systemic cytokines, speciﬁcally IL-6, in LRRK2
mice? and (ii) do these cytokines act on the CNS indirectly by
inducing release of other soluble mediators from the immune
cells located closest to the brain, in the meninges?
IL-6 was originally isolated from macrophages and T-cells as a
B-cell growth factor which plays an important role in antibody
production and class switching86,87. However, recent studies have
suggested that a signiﬁcant amount of IL-6 (in some cases much
higher than in macrophages) can be produced by B-cells in
response to LPS88–90. Given these features of IL-6, along with our
previous observation of signiﬁcant upregulation of mutant LRRK2
expression in CD19+ B-cells upon in vivo LPS treatment52, it is
possible that this sub-population of immune cells is a major
contributor to IL-6 overproduction. In fact, ongoing experiments in
our lab suggest that a speciﬁc deletion of mutant LRRK2 in CD19+
B-cells might have a neuroprotective effect on SNpc DA neurons
following LPS administration. Since the meninges are highly
populated by many different bloodstream-derived immune cell
npj Parkinson’s Disease (2022) 24

including B-cells, each of which can release various cytokines into
the CSF65,66,70,91,92, it is plausible to speculate that mutant LRRK2
might mediate its neurotoxic effect via disrupted meningealimmune cell trafﬁcking and cytokine signaling.
Two recent studies strongly implicate meningeal lymphatic
dysfunction in the pathogenesis of PD. Animal experiments
showed that blocking extracranial lymphatic drainage markedly
exacerbates accumulation of α-synuclein in the brain of A53T mice
and subsequently leads to extensive reactive astrogliosis93.
Second, using dynamic contrast-enhanced MRI, it was found that
patients with idiopathic PD exhibited signiﬁcantly reduced ﬂow
through the meningeal lymphatic vessels along the superior
sagittal sinus and sigmoid sinus, as well as a notable delay in deep
cervical lymph node perfusion94. Thus, in future studies, it will be
very important to determine whether pathogenic mutations in
LRRK2 result in the accumulation of peripherally-derived B-cells in
the meninges, and whether interference with the bloodstream ->
meninges trafﬁc and/or meningeal cytokine production would
inﬂuence neuronal loss and the development of a parkinsonian
neuropathological phenotype.
Our results suggesting that peripheral IL-6 is critical to
inﬂammation-mediated LPS-induced neuronal death are also
interesting in light of a recent in vitro study showing that
wtLRRK2 modulates the production of TNF-α and IL-6 in αsynuclein-exposed mouse microglia; this effect being mediated
through increased nuclear translocation of NFATc281. Previously,
NFATc2, which is known to play a critical role in T- and B-cell
activation and differentiation, was shown to transcriptionally
regulate the expression of IL-6 and IL-6R in different types of
immune cells95–99. WtLRRK2 was suggested as a negative
regulator of NFATc2 based on its interactions with noncoding
RNA repressor of NFATc2 to inhibit nuclear translocation80, and it
was proposed that selective blocking NFATc2 phosphorylation by
LRRK2 inhibition may prevent toxic inﬂammation. Further in vivo
studies would be incredibly valuable to determine whether the
aberrant inﬂammatory response and SNpc DA neuron loss are
mediated via dysregulation of the LRRK2-NFATc2 pathway in
peripheral and/or meningeal immune cell subsets. It is also
important to note that IL-6 represents a reasonable target since its
concentration was shown to be increased in the nigrostriatal
region and CSF of idiopathic PD patients as well as bi-allelic
PARKIN carriers100,101. Additionally, it will be crucial to examine
whether the IL-6 mAb-mediated neuroprotection sustains for a
signiﬁcant period of time (months).
It is also worth noting that the neutrophil-to-lymphocyte ratio in
blood is signiﬁcantly higher in PD patients compared to healthy
controls102. Given that LRRK2-expressing neutrophils76 are the
most powerful source of ROS, these cells may play an important
role as signaling messengers in the immune system such that
abnormal oxidative stress levels in activated circulating neutrophils might also contribute to a dysregulated immune response. In
addition, neutrophils are also present in the CSF and meninges,
and express high level of Rab10 which is known to regulate
phagosomal recycling103, and future research will address this
questions.
In addition to understanding of the mechanisms by which
LRRK2 may exert its pathogenesis in the development of PD, our
studies also have implications for therapeutic approaches to
prevent or slow the progression of this disease. Our ﬁndings
support the hypothesis that signals emanating from the peripheral
adaptive immune system are the initiator of the cascade that
eventually leads to development of PD pathology. A number of
compounds that block the effects induced by mutations in LRRK2
are currently in development, with a number of these in early
Phase II clinical trials. One of the issues facing development of this
class of drugs is the need to ﬁnd a BBB-penetrant drug that can
penetrate into the brain in sufﬁcient quantities to inhibit the
neurotoxic effect of mutant LRRK2. This often requires higher
Published in partnership with the Parkinson’s Foundation
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doses of the drug than would be necessary to inhibit the enzyme
in the periphery alone where cell accessibility is signiﬁcantly
improved. Our studies, in respect to LRRK2 carriers, suggest that
CNS-penetrant forms of LRRK2 inhibitors might not be necessary;
and that if treatment is started early enough in identiﬁed mutant
LRRK2 carriers, the abnormal inﬂammatory signals that originate in
the periphery could be normalized; which we hypothesize will
reduce or eliminate the initiation of a pathogenic cascade in the
brain. Given that these compounds exist, this mechanism for
normalizing abnormal LRRK2 signaling in the periphery can be
empirically tested. Additionally, it will be useful to examine if the
primacy of the immune system in disease initiation that we
describe in this study is speciﬁc to the LRRK2 mutations or if this a
commonality to other familial PD genes that are shown to be “risk
factors” rather than direct drivers of the disorder.
METHODS
Animals and generation of double-mutant mice
One to ﬁve months old WT (C57BL/6J), C57BL/6J-Tg(LRRK2*R1441G)3IMjff/
J, C57BL/6-Tg(UBC-GFP)30Scha/J, B6.129S7-Rag1tm1Mom/J mice (all Jackson
Laboratory, Bar Harbor, ME) and C57BL/6-Lrrk2tm4.1Arte (Taconic, NY)
were used in this study. In all experiments, age- and background strainmatched mice were used as controls. Equal number of males and females
were used in the study since, in our hands, no differences in the
neuropathological phenotype (the number of TH neurons) were observed
between two sexes both at baseline and after LPS exposure37 (data not
shown). C57BL/6J-Tg(LRRK2*R1441G)3IMjff/J mice (referred to hereinafter
as R1441G) overexpress a human mutant LRRK2 (directed by the human
LRRK2 promoter on the BAC transgene) in the brain (SN and striatum) and
PBMCs at an approximately two- and four-fold greater levels than the
endogenous mouse LRRK2, respectively52. A human LRRK2 transgene
insertion site was previously located in mChr 152. The C57BL/6Lrrk2tm4.1Arte mouse strain (referred to hereinafter as G2019S) is a
constitutive KI of the mouse LRRK2 gene. The human G2019S gain-ofkinase activity mutation was introduced into exon 41 of the mouse LRRK2
gene using C57BL/6 J BAC–DNA. KI mice were crossed to WT C57BL/6NTac
every fourth generation to guard against genetic drift. Similar to the
previously described LRRK2 KI and transgenic models, this strain does not
develop age-related loss of DA neurons104.
In order to generate double mutant mice, homozygous B6.129S7Rag1tm1Mom/J mice (referred to hereinafter as Rag1−/−) mice were crossed
with transgenic R1441G mice to ﬁrst generate heterozygous Rag1-/
+
/R1441Gwt/tg mice which were next intercrossed to generate homozygous
double mutant Rag1−/−/R1441Gtg/tg mice (referred to hereinafter as Rag1/
R1441G). Genotypes of all strains were determined by PCR of tail DNA
using protocols from Jackson Laboratory. All experimental procedures
were performed under pathogen-free conditions. All animals were housed
within the vivarium at Thomas Jefferson University and maintained on a
12:12 h (h) light/dark cycle with ad libitum food and water. All of the
experimental procedures in the animals were performed in accordance
with the NIH Guide for the Care and Use of Laboratory Animals and all
protocols were approved by the Thomas Jefferson University IACUC
(Protocol 1892). Experiments were carried out in accordance with The
Code of Ethics of the World Medical Association (Declaration of Helsinki)
for animal experiments.

were transplanted with BM-derived from homozygous R1441G or G2019S
donor mice (8–15 wk old; 20 × 106 cells). All resulted chimeras (WT(GFP) ->
Rag1, WT(GFP) -> Rag1/R1441G, R1441G ->Rag1 and G2019S ->Rag1) were
monitored 2 times/week ﬁrst 2 weeks post-BMT for any signs of rejection
and once per week thereafter. NaCl- or LPS-treated 4-5 months old WT
(C57BL/6J), Rag1−/−, R1441G, and G2019S mice were used as controls for
chimeric strains.

LPS and neutralizing antibody administration
Eight weeks post-BMT, chimeras were injected i.p. with 5 mg/kg LPS (E.coli
serotype O111:B4; Sigma–Aldrich MO, USA). Immediately after LPS
injection, mice were placed on warming pads in order to prevent
hypothermia and reduce mortality106,107. Mice were monitored daily for
the next 7 days. All experimental procedures were performed under
pathogen-free conditions. In cytokine neutralization experiments, 2 h postLPS mice received either anti-IL-6 monoclonal neutralizing antibodies
(2.5 mg/kg body weight, i.v.; Thermo Fisher, USA) or control IgG (Thermo
Fisher, USA) in 200 μl of sterile saline via injection into the lateral tail vein.

Peripheral blood mononuclear cells separation
Blood was collected from the heart of deeply anesthetized mice into 10%
EDTA-treated vacuum tubes, mixed 1:1 with sterile PBS, and separated in
lymphocytes separation medium (Corning, NY USA). Samples were
centrifuged for 30 min at 400 g at RT and then the leukocytes “white”
layer was carefully aspirated and placed into sterile tubes. Cells were
washed with sterile PBS, centrifuged for 10 min at 200 g at RT, and then
immediately used for Flow Cytometry or FACS.

Flow cytometry and FACS
To characterize the immune phenotype of double mutant mice and verify
the reconstitution of T- and B-lymphocyte populations in BM-transplanted
mice, spleen and PBMCs were collected and after single-cell suspension
was obtained, stained with antibodies directed against CD4, CD8, CD19,
CD11b, and DAPI (all from BD Biosciences, San Diego CA). After eliminating
debris/dead cells (DAPI-positive) and doublet cells by forward- and sidescatter, cells were gated based on CD4 (PerCP-Cy5.5), CD8 (PE-Cy7), CD19
(APC-Cy7), CD11b (Alexa700) and/or GFP ﬂuorescent intensity. A small
portion of the cells was incubated without antibodies to gate cells
according to their light scattering characteristics, and another small
portion of the cells was stained with isotype-matched control reagents to
set the maximum threshold for non-speciﬁc binding. Data were acquired
using a FACSCalibur ﬂow cytometer (BD Biosciences, San Diego CA) and
analyzed with CellQuest Pro (BD Biosciences, San Jose, CA) software. The
ﬁnal ﬂow data in control mice and double mutants were represented as
the percentage of each sub-population (CD4+, CD8+, CD19+) to the total
number of live cells analyzed. The ﬁnal data in BM-transplanted chimeras
were represented as the percentage of GFP + cells to the total number of
live cells. Homozygous GFP+/+ and Rag1−/− mice were used as positive
and negative controls, respectively. For FACS, PBMCs were isolated from
double mutant transplanted chimeras (WT(GFP) -> Rag1/R1441G) and
sorted for GFP+/CD4+, GFP+/CD8+, GFP+/CD19+ as well as for GFPnegative signal using a FACSAria cell sorter. The viability of sorted cell
populations was always at least 95%. After sorting, cells were washed with
sterile PBS, centrifuged, and stored at −80 °C until assayed.

RT-qPCR
Bone marrow isolation and transplantation
In order to generate chimeric mice, 5-6 week old recipient Rag1−/− mice44
or double mutant Rag1/R1441G mice lacking T- and B-cells were injected
i.v. with bone marrow (BM) cells derived from donor sex- and MHCmatched homozygous C57BL/6-Tg(UBC-GFP)30Scha/J (referred to hereinafter as WT(GFP) mice). BM cells were isolated from the femurs and tibias
of euthanized 8–15 wk old donor mice, treated with RBC lysis buffer,
washed, and 20 × 106 cells in 200 ul of sterile saline were immediately
injected into the lateral tail vein. Only freshly isolated BM cells were used in
the study. Donor WT(GFP) mice have a ubiquitin promoter-driven GFP
transgene expressed throughout all hematopoietic cell subsets and
developmental stages and were generated directly in the C57BL/6 strain
making this strain ideal for cell-transfer experiments into C57BL/6
recipients105. To generate “reversed” chimeras (referred to hereinafter as
R1441G ->Rag1 or G2019S ->Rag1), immunodeﬁcient Rag1−/− recipients
Published in partnership with the Parkinson’s Foundation

FACS-sorted cells were processed to obtain RNA in accordance with the
protocol outlined in PureLink® RNA Mini Kit or ARCTURUS® PicoPure® RNA
isolation Kit (Thermo Fisher Scientiﬁc, MA, USA). The RNA samples were
treated with DNase (Thermo Fisher Scientiﬁc, MA, USA) and total RNA was
quantiﬁed using a NanoDrop 8000 (Thermo Fisher Scientiﬁc, MA, USA).
Isolated RNA was converted to cDNA using a High-Capacity RNA to cDNA
kit (Applied Biosystems, CA, USA) according to manufacturer instructions.
This cDNA was subsequently used for RT-qPCR analysis using speciﬁc
validated primers (Taqman® assays) obtained from Life Technologies.
Reactions were performed using TaqMan Gene Expression Master Mix or
TaqMan® Fast Advanced Master Mix in a 7300 Real-Time PCR System or
7500 Fast Real-Time PCR System (Applied Biosystems, USA), respectively.
β-actin gene was used as the normalizing/housekeeping gene. Gene
expression was expressed as 2−ΔΔCt denoting fold-change in mRNA levels
for each gene.
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Luminex and ProcartaPlex assays
For cytokine assays, blood was collected into EDTA-treated tubes. Serum
was separated by centrifugation and stored at −20 °C until assay. Brain
tissues were mechanically homogenized in Bioplex cell lysis buffer
containing factors 1 and 2 (Bio-Rad, CA, USA) and centrifuged at 4500 ×
g. The total protein concentration of each sample was determined using
the BCA assay (Pierce, IL, USA), with bovine serum albumin as a standard,
according to the manufacturer’s protocol. Individual vials of cytokines/
chemokines beads were sonicated, vortexed and then mixed with assay
buffer (Milliplex Map Kit, MCYTOMAG-70K, Millipore, MA, USA). Working
standards were made by diluting the stock concentration (10,000 pg/ml) in
assay buffer. Brain and serum samples were added in equal volumes (25 μl)
into the wells (96-well plate) containing 25 μl of assay buffer and 25 μl of
cytokines mixed beads and plate was incubated overnight at +4 °C. Then
plate was washed and incubated following: (i) with detection antibodies,
(ii) Streptavidin-Phycoerythrin, (iii) sheath ﬂuid. The plates were run on a
Luminex 200TM according to manufacturer’s recommended procedures
and the data analyzed using BioPlex Manager 4.1 software (Bio-Rad,
Hercules, CA). All samples were run in duplicates. Data were expressed as
pg/mg total protein. Final data in LPS-treated groups are expressed as the
percentage of NaCl control.
The antibody assay was performed on serum using Mouse Antibody
Isotyping 7-Plex ProcartaPlex Panel (Invitrogen, Waltham, MA) measuring
the antibody isotypes IgA, IgE, IgG1, IgG2a, IgG2b, IgG3, and IgM. The
antibody assay was performed according to the manufacturer’s instructions. The plates were read on Luminex 200TM according to manufactures
recommended procedures and the data analyzed using BioPlex Manager
4.1 software.

Immunohistochemistry
Mice were intracardially perfused with 1× phosphate-buffered saline (PBS),
pH 7.4. followed by 3% paraformaldehyde in PBS, pH 7.4. Each brain was
dissected out of the skull following perfusion and post-ﬁxed overnight in
fresh ﬁxative. Brains were then dehydrated through a graded series of
ethanols, defatted in mixed xylenes and embedded in parafﬁn (ParaplastXtra™, Fisher Scientiﬁc), and then blocked and cut in the coronal plane and
serially-sectioned at 10 µm. Every section from the rostral hippocampus to
the anterior aspects of the cerebellar-midbrain junction was saved and
mounted, ﬁve sections per slide, onto Superfrost-Plus slides (Fisher
Scientiﬁc, MA, USA). Every other slide (ﬁrst series) was double labeled for
TH (1:250; mouse monoclonal, T1299, Sigma-Aldrich, MO, USA) and ionized
calcium-binding adapter molecule 1 (Iba-1) (1:200; rabbit polyclonal,
019–19741, Wako), VA, USA) as described previously108. The double
labeling was carried out using a two-color DAB protocol. In some
experiments, a second series of sections were labeled for T-cells (CD3,
1:300; Armenian hamster, 14-0031-82, Santa Cruz Biotechnology, TX, USA).
All sections were then counterstained with a Nissl stain (Neutral Red or
cresyl violet).
To examine whether GFP-positive donor BM cells colonize the CNS and
differentiate into microglia and/or astrocytes in non-treated and LPStreated chimeras, 10um coronal brain sections were stained with Iba-1
(1:500; goat polyclonal, ab5076, Abcam, USA) or GFAP (1:250; mouse
monoclonal, G3893, Sigma, USA). Then sections were washed and
incubated with anti-goat or anti-mouse Alexa Fluor 633 antibodies (Life
Technologies, NY, USA) and analyzed for co-expression of GFP in Iba-1+
and GFAP+ cells. Sections incubated without primary antibody were used
as a negative control. Iba-1-stained spleen sections from double mutant
chimeras were used as a positive control for GFP + donor cell engraftment.

Microscopy and model-based stereology
The total number of SNpc TH-positive DA neurons as well as Iba-1-positive
microglial cells was estimated using model-based stereology109,110. On
average, forty sections per SNpc were analyzed. TH-positive or Iba-1positive cells were counted as present within a section if they exhibited
DAB (TH) or VIP (Iba-1) reaction product in the cytoplasm and there was a
clear and complete nucleus present. For DA neurons, we also noted the
presence of TH-, Nissl + DA neurons, but these were rarely identiﬁed.
Microglia were also quantiﬁed. These cells were deemed as “resting” if it
contained a small oval Iba-1-positive cell body that averaged three microns
or less in diameter with long slender processes, and as “activated” when
the cell body was increased in size compared to resting microglia and
had an irregular shape with shorter and had thickened processes111.
Double-stained GFP/Iba-1 and GFP/GFAP sections were examined with a
npj Parkinson’s Disease (2022) 24

ﬂuorescent microscope (Olympus BX51, Olympus Corporation, Tokyo,
Japan) under 10× and 20× objectives.

Statistical analysis
All data are represented as mean ± SEM. Statistical analysis was performed
using the GraphPad Prism® version 4.03 software. Differences between
groups were determined by t-test (2 groups) or one-way ANOVA (more
than two groups). If overall statistical signiﬁcance was found using ANOVA,
post hoc comparisons (Tukey) were performed.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
There are no data in this paper that can be submitted to a data repository. Data as
reported in this paper show each data point and no data have been excluded from
the analysis.
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